In The News

Guest Commentary: Targeting α-synuclein and the pathogenesis of Parkinson’s disease

Attacking the Right Therapeutic Target in Alzheimer’s Disease

Could Roche’s Alzheimer’s drug failure be Promis Neurosciences gain?

ProMIS tackles Parkinson's and Alzheimer’s diseases

ProMIS Neurosciences (TSX:PMN): Targeting the root cause of Alzheimer’s and other neurodegenerative diseases

Stockhouse - The Key to Unlocking Alzheimers Treatment?

Global Business Report – Interview with Eugene Williams Executive Chairman, ProMIS

ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates

Why Hope Endures For An Alzheimer's Treatment — And Biogen Could Be First

ProMIS Trial Offers Hope For Alzheimer's Patients